Professor Bronwyn Kingwell’s fundamental and clinical research in arterial biomechanics has driven new approaches and international guidelines for the management of arterial diseases including Marfan syndrome and peripheral artery disease. She has pioneered the transition of detailed cellular and molecular studies of high-density lipoprotein (HDL) in laboratory models, in particular with regard to glucose metabolism, to a human context. This work has opened major new avenues in HDL therapeutics for treatment of diabetes. Her contributions have also influenced national and international physical activity guidelines. Professor Kingwell has been a leader in defining Australian science policy and is an active mentor.